AstraZeneca Cancer Drug MEDI4736 Data Supports further Trials

Filed under Health

On Tuesday, Britain’s AstraZeneca said that MEDI4736 experimental cancer drug clinical trials were supporting the immunotherapy cancer treatment and has opened new gates of testing.

In Chicago, AstraZeneca presented its data at the annual American Society of Clinical Oncology (ASCO) meeting.

MEDI4736 is a type of drug that blocks the tumor formation by inhibiting its activities against the immune system’s defenses. This class of drug is renowned as anti-PDL1 therapies.

AstraZeneca reported the responsiveness in multiple cancer type patients including cutaneous melanoma, non-small lung cancer, gastroesophageal cancer, squamous cell carcinoma of the head and neck, and pancreatic cancer.

In the Phase I clinical trial, in 27 patients, MEDI4736 has produced pronounced effects in the patients of melanoma, non-small cell lung cancer and colorectal cancer. Tumor shrinkage was seen in 19 percent patients and 39 percent has stabilized cancer after a year of treatment.